Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
Unleashing the Power of Torsemide: A Comprehensive Review on R&D Breakthroughs
Drug Insights
4 min read
Unleashing the Power of Torsemide: A Comprehensive Review on R&D Breakthroughs
30 September 2023
This article summarized the latest R&D progress of Torsemide, the Mechanism of Action for Torsemide, and the drug target R&D trends for Torsemide.
Read →
SELLAS announces promising initial results from the SLS009 Phase 1 lymphoma group study, advancing to Phase 2 clinical trial
Latest Hotspot
3 min read
SELLAS announces promising initial results from the SLS009 Phase 1 lymphoma group study, advancing to Phase 2 clinical trial
30 September 2023
SELLAS reveals uplifting preliminary findings in Lymphoma group from SLS009 Phase 1 Increasing-Dose Study, promoting progression to Phase 2 Clinical Experiment.
Read →
A Comprehensive Review of Nabumetone's R&D Innovations and Drug Target Mechanism
Drug Insights
4 min read
A Comprehensive Review of Nabumetone's R&D Innovations and Drug Target Mechanism
30 September 2023
This article summarized the latest R&D progress of Nabumetone, the Mechanism of Action for Nabumetone, and the drug target R&D trends for Nabumetone.
Read →
Advances in Clinical Research on PARP1 inhibitors
Advances in Clinical Research on PARP1 inhibitors
30 September 2023
PARP1 is the most prominent member of the PARP family, accounting for 80%-90% of the enzyme activity, and is a key player in DNA damage repair.
Read →
Pharmaceutical Insights: Thiocolchicoside's R&D Progress and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Pharmaceutical Insights: Thiocolchicoside's R&D Progress and its Mechanism of Action on Drug Target
30 September 2023
This article summarized the latest R&D progress of Thiocolchicoside, the Mechanism of Action for Thiocolchicoside, and the drug target R&D trends for Thiocolchicoside.
Read →
Krystal Biotech reports FDA approval of the investigational new drug application for KB408 to treat Type 1 Alpha-1 Antitrypsin Deficiency
Latest Hotspot
3 min read
Krystal Biotech reports FDA approval of the investigational new drug application for KB408 to treat Type 1 Alpha-1 Antitrypsin Deficiency
30 September 2023
Krystal Biotech publicized that the U.S. FDA has given the green light for the Investigational New Drug application for KB408 to manage alpha-1 antitrypsin deficiency.
Read →
Exploring Tianeptine Sodium's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
Drug Insights
4 min read
Exploring Tianeptine Sodium's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
30 September 2023
This article summarized the latest R&D progress of Tianeptine Sodium, the Mechanism of Action for Tianeptine Sodium, and the drug target R&D trends for Tianeptine Sodium.
Read →
Analysis on the Clinical Research Progress of PDL1 inhibitors
Analysis on the Clinical Research Progress of PDL1 inhibitors
30 September 2023
Programmed death-ligand 1 (PD-L1) is a protein found on the surface of certain cells in the human body, including immune cells and some cancer cells.
Read →
Decoding Tibolone: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
Drug Insights
4 min read
Decoding Tibolone: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
30 September 2023
This article summarized the latest R&D progress of Tibolone, the Mechanism of Action for Tibolone, and the drug target R&D trends for Tibolone.
Read →
The European Commission has approved Jazz Pharmaceuticals' Enrylaze® for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma treatment
Latest Hotspot
3 min read
The European Commission has approved Jazz Pharmaceuticals' Enrylaze® for Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma treatment
30 September 2023
Jazz Pharmaceuticals plc has proclaimed that the EC has approved the commercialization of Enrylaze®(JZP458; a derivative of Erwinia asparaginase or crisantaspase).
Read →
Deep Scientific Insights on Tofacitinib Citrate's R&D Progress, Mechanism of Action, and Drug Target
Drug Insights
4 min read
Deep Scientific Insights on Tofacitinib Citrate's R&D Progress, Mechanism of Action, and Drug Target
30 September 2023
This article summarized the latest R&D progress of Tofacitinib Citrate, the Mechanism of Action for Tofacitinib Citrate, and the drug target R&D trends for Tofacitinib Citrate.
Read →
Cardiovascular Disease Treatment Drug - PDE3 Inhibitors
Cardiovascular Disease Treatment Drug - PDE3 Inhibitors
30 September 2023
PDE3 has the ability to hydrolyze both cAMP and cGMP, but its ability to hydrolyze cAMP is about ten times that of cGMP.
Read →